SCYNEXIS Stock

SCYNEXIS CapEx/D&A

CapEx to Depreciation Ratio of SCYNEXIS (SCYX) as of Aug 4, 2026.

CapEx/D&A

0.00

Last updated:

CapEx to Depreciation Ratio of SCYNEXIS is 2026 0.00 . CapEx to Depreciation Ratio of SCYNEXIS was 2025 0.00 . It decreases by % lower compared to the previous year.
Access this data via the Eulerpool API

SCYNEXIS Stock analysis

What does SCYNEXIS do? SCYNEXIS Inc is a biopharmaceutical company that focuses on the discovery and development of novel therapeutics for serious infectious diseases and cancer. The company was founded in 2000 and is headquartered in New Jersey, USA. SCYNEXIS is one of the most popular companies on Eulerpool.

Frequently Asked Questions about SCYNEXIS stock

On Eulerpool you can find the complete historical development of CapEx to Depreciation Ratio SCYNEXIS since 2006 – with annual values, charts, and detailed analysis.

The CapEx/D&A ratio compares investment spending to asset depreciation. Ratios above 1.0x indicate the company is growing its asset base, below 1.0x suggests underinvestment.

A 'good' varies by industry and company stage. On Eulerpool, you can compare CapEx to Depreciation Ratio's SCYNEXIS with sector peers and the industry average to assess whether it is attractive.

To evaluate CapEx to Depreciation Ratio's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for CapEx to Depreciation Ratio.

Access this data via the Eulerpool API

Cash Flow — SCYNEXIS

All Key Metrics — SCYNEXIS